Accumulation of mutant p53 protein occurs frequently in human malignancies, including 40-60% of non-small cell lung carcinomas. The implications of such p53 over-expression, usually assessed by immunohistochemical techniques, for the prognosis of lung cancer patients remain undetermined. In this stu
Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients
✍ Scribed by Weimin Gao; Hussam H. Mady; Mona F. Melhem; Phouthone Keohavong
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 163 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20505
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Our previous study showed a characteristic p53 mutational spectrum in lung tumors from lung cancer patients in the Western Pennsylvania region. To further understand the involvement of p53 mutations in lung tumor development, in this study we compared p53 mutational spectra and distribution between tumor cells taken from lung tumor tissue and histologically normal cells taken from tumor‐surrounding tissue obtained from 122 lung cancer patients [67 adenocarcinomas (ACs) and 55 squamous cell carcinomas (SCCs)]. Overall, mutations were detected in exons 5–8 of the p53 gene in cell samples from 39.3% (48/122) of the patients. Twenty‐four mutations were found among the ACs (35.8%, 24/67) and consisted mostly of G to T transversions at codon 248 in either only the tumor tissue (12 cases, 50%), or only the histologically normal tissue (2 cases, 8.3%), or both tissue types (10 cases, 41.7%). Among the SCCs, 24 mutations of both transition and transversion types were detected at multiple codons in either only the tumor tissue (17 cases, 70.8%), or only the histologically normal tissue (3 cases, 12.5%), or both tissues (4 cases, 16.7%). Overall, the distribution of mutations among the tumor tissue and histologically normal tissue was not significantly different between the ACs and SCCs (P > 0.05). In both groups, the mutations in the histologically normal tissue may be identical to or different from those in the tumor tissue. Therefore, p53 mutations are frequent in tumor‐surrounding histologically normal tissue, and some of them might be involved in lung carcinogenesis. © 2008 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Validated markers are needed to identify operable lung cancer patients with poor prognosis. About one-half of nonsmall-cell lung cancers (NSCLCs) carry a mutation in the p53 tumor-suppressor gene. We examined 101 NSCLC patients for surgical stage, completeness of resection, tobacco smoking, asbestos
Fifty-two sporadic primary non-small-cell lung carcinomas (NSCLC) were examined for microsatellite instability. Six different microsatellite markers localized on chromosomes 2, 5, 8, 10, 11 and 17 were used. Genomic instability was observed in 35% (18/52) of NSCLC at single or multiple loci. The tum
## Abstract Mounting evidence has suggested somatic mutations in the __EGFR__ gene are associated with better responsiveness to __EGFR__ tyrosine kinase inhibitors (TKIs) in patients with non‐small‐cell lung cancer (NSCLC). Some, but not all, studies have reported that the mutations were more frequ
## Abstract Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the etiopathogenesis of lung cancer and is a promising tool for cancer detection. In the present study, promoter hypermethylation of __p16^INK4A^__ and __CDH13__ genes was inv
p53 tumour suppressor gene alterations are one of the most frequent genetic events in lung cancer. A subset of patients with p53 mutation and cancer exhibited circulating serum anti-p53 self-antibodies (p53-Ab). The prevalence of these antibodies in lung cancer is currently being analysed in a multi